Díez Juan J, Alcázar Victoria, Iglesias Pedro, Romero-Lluch Ana, Sastre Julia, Corral Begoña Pérez, Zafón Carles, Galofré Juan Carlos, Pamplona María José
Department of Endocrinology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana, Majadahonda, Madrid, Spain.
Gland Surg. 2021 Feb;10(2):678-689. doi: 10.21037/gs-20-712.
Total thyroidectomy is the standard initial surgery for differentiated thyroid carcinoma (DTC), but the extent of the thyroidectomy remains controversial. Thyroid lobectomy (TL) has been widely used in eastern countries; however, its use has not been generalized in western countries, including Spain. Our aims were to analyse the clinical outcome of a multicentre nation-wide cohort of DTC patients treated by TL and to assess the proportion of patients who required completion of the thyroidectomy and who presented disease recurrence.
We retrospectively analyzed patients who underwent TL for DTC and were followed-up for ≥12 months. We collected demographic, clinical, and histopathological data. Dynamic risk stratification (DRS) was performed at 12 months and at last visit.
One hundred and sixty-four patients (128 women, mean age 50.8 years, median follow-up 45.4 months) from 9 hospitals were included. There were 158 cases of papillary and 6 of follicular thyroid carcinoma (FTC). Remission of the disease (excellent response) was shown in 71.6% of the patients at 12 months and in 74.4% at the end of follow-up. At that time, there were 34 patients (20.7%) with indeterminate response, 6 (3.7%) with biochemical incomplete response, and 2 (1.2%) with structural incomplete response. Completion of the thyroidectomy was necessary in 8 patients (4.9%), but only 3 of them (1.8%) had disease recurrence.
These results, obtained in real clinical practice, suggest that TL is a safe operative option for selected patients with DTC and that the intensity of the treatment must be tailored according to the presurgical tumor-associated risk, in line with a personalized medicine.
全甲状腺切除术是分化型甲状腺癌(DTC)的标准初始手术,但甲状腺切除术的范围仍存在争议。甲状腺叶切除术(TL)在东方国家已被广泛应用;然而,在包括西班牙在内的西方国家,其应用尚未普及。我们的目的是分析多中心全国性队列中接受TL治疗的DTC患者的临床结局,并评估需要完成甲状腺切除术和出现疾病复发的患者比例。
我们回顾性分析了接受TL治疗DTC并随访≥12个月的患者。我们收集了人口统计学、临床和组织病理学数据。在12个月和最后一次随访时进行动态风险分层(DRS)。
纳入了来自9家医院的164例患者(128例女性,平均年龄50.8岁,中位随访45.4个月)。其中有158例乳头状甲状腺癌和6例滤泡状甲状腺癌(FTC)。12个月时71.6%的患者疾病缓解(良好反应),随访结束时为74.4%。当时,有34例患者(20.7%)反应不确定,6例(3.7%)生化反应不完全,2例(1.2%)结构反应不完全。8例患者(4.9%)需要完成甲状腺切除术,但其中只有3例(1.8%)出现疾病复发。
在实际临床实践中获得的这些结果表明,TL对于选定的DTC患者是一种安全的手术选择,并且治疗强度必须根据术前肿瘤相关风险进行调整,这符合个性化医疗。